Who Paid My Doc
Mark Schroeder
Medical Oncology Saint Louis, MO Medical Doctor
NPI 1255544680 CMS profile 192719
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5Th, 6Th, 8Th Fl, Saint Louis, MO 63108
General payments
$197,677
Research payments
$131,341
Ownership & investment interest
$0
Research they led as principal investigator
$2,387,862
Through program year 2025, Mark Schroeder of Saint Louis, MO is reported in the CMS Open Payments database as having received $197,677 across 47 general payments and $131,341 in research payments paid to them. Separately, studies naming them as principal investigator received $2,387,862 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $63,113 | 4 | |
| 2025 | Research | $9,356 | 25 | |
| 2024 | General | $39,602 | 5 | |
| 2024 | Research | $40,904 | 23 | |
| 2023 | General | $46,700 | 2 | |
| 2023 | Research | $64,898 | 27 | |
| 2022 | General | $7,146 | 4 | |
| 2022 | Research | $225 | 1 | |
| 2021 | General | $6,950 | 2 | |
| 2021 | Research | $3,888 | 10 | |
| 2020 | General | $6,658 | 4 | |
| 2020 | Research | $1,050 | 3 | |
| 2019 | General | $27,509 | 26 | |
| 2019 | Research | $11,022 | 9 |
Beside peers
- Mark Schroeder
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Mark Schroeder were reported at $63,113. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Mark Schroeder | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $27,509 | $968 | $140–$6,658 | $163 |
| 2020 | $6,658 | $747 | $102–$5,891 | $114 |
| 2021 | $6,950 | $430 | $50–$4,098 | $132 |
| 2022 | $7,146 | $812 | $127–$4,907 | $149 |
| 2023 | $46,700 | $957 | $144–$5,248 | $160 |
| 2024 | $39,602 | $1,042 | $149–$5,650 | $164 |
| 2025 | $63,113 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
1,218
Drug cost
$10,850,190
Branded share of claims
56.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 248 | $4,766,801 | |
| Lenalidomide | Generic | 174 | $2,698,906 | |
| Pomalyst Pomalidomide | Brand | 116 | $2,677,357 | |
| Jakafi Ruxolitinib Phosphate | Brand | 21 | $300,107 | |
| Tasigna Nilotinib Hcl | Brand | 12 | $228,040 | |
| Cresemba Isavuconazonium Sulfate | Brand | 12 | $79,195 | |
| Eliquis Apixaban | Brand | 66 | $46,311 | |
| Xarelto Rivaroxaban | Brand | 16 | $14,727 | |
| Posaconazole | Generic | 12 | $12,473 | |
| Oxycontin Oxycodone Hcl | Brand | 13 | $11,935 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 121 billing codesPaid by Medicare
$732,283
Medicare patients
372
Services billed
35,079
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Chronic kidney disease | 38% | |
| Cancer | 33% | |
| Diabetes | 32% | |
| Ischemic heart disease | 30% | |
| Depression | 30% | |
| Heart failure | 27% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 21 | 5,040 | $193,025 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 11 | 42 | $5,898 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 14 | 68 | $328 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 13 | 2,100 | $210 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 18 | 210 | $158 |
| Infusion, normal saline solution , 1000 cc J7030 | Office | 15 | 25 | $51 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 32 | 540 | $46 |
| Injection, granisetron hydrochloride, 100 mcg J1626 | Office | 12 | 160 | $41 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 13 | 21 | $13 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| SARCLISA |
|
$964 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
145 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Medical Oncology in Missouri
Leonid Shunyakov
Medical Oncology · Bolivar, MO
Timothy Pluard
Medical Oncology · Kansas City, MO
Brad Kahl
Medical Oncology · Saint Louis, MO
Michael Naughton
Medical Oncology · Cape Girardeau, MO
Russell Pachynski
Medical Oncology · Saint Louis, MO
George Ansstas
Medical Oncology · Saint Louis, MO
Related records
Medical Oncology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.